Phaseline

Companies › Medolution

Medolution: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Keynatinib
BTK inhibitor
BTKPhase 1Lymphoma, B-CellOct 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04807881KeynatinibPhase 1Lymphoma, B-CellOncologyOct 2032

Targets

BTK (1)

Companies with the same targets

Sanofi BeOne Medicines Eli Lilly AstraZeneca Guangzhou Lupeng Pharmaceutical Company Zenas BioPharma (USA) Carna Biosciences Merck & Co. (MSD) Acerta Pharma Beijing InnoCare Pharma Tech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.